Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Clinical Study to Assess High-DHA Fish Oil on Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy

Clinical Study to Assess the Acute and Chronic Effects of a High-DHA Fish Oil on Fasting and Post-Prandial Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy.

The objective of this study is to determine the acute and chronic [4-week] effects of a high-DHA fish oil supplement on fasting and post-prandial (post-meal) biomarkers of cardiovascular disease risk, in adults on Statin therapy.

Studieöversikt

Status

Avslutad

Detaljerad beskrivning

This study involves fasted and post-prandial components.

Fasted Study:

Participants will provide fasting blood samples pre-and post-intervention [4-week administration of supplement or placebo] in Treatment Period I. Participants will again provide fasting blood samples pre-and post-intervention [4-week administration of supplement or placebo, opposite to Treatment Period I] during Treatment Period II.

There will be a 4-week washout period during the two Treatment Periods.

Post-prandial study:

Participants will also complete a post-prandial study pre-and post-intervention during each Treatment Period.

Studietyp

Interventionell

Inskrivning (Förväntat)

36

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Ontario
      • Guelph, Ontario, Kanada, N1G 0B4
        • Nutrasource Diagnostics Inc.

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 70 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Be an adult between the ages of 18 and 70;
  • Be a male or a post-menopausal female who has gone a minimum of one year since their last menses;
  • Be taking Statin medication at a stable dose for a minimum of four weeks prior to study commencement [and whom have reached a target LDL level];
  • Have elevated fasting triglyceride levels [greater than 1.5 mmol/L but less than 5.7 mmol/L];
  • Have fasting blood glucose levels below the study cut-off [less than 7.0 mmol/L];
  • Have a Body Mass Index (BMI) less than 35.0
  • Be taking natural health products BUT agree to cease consumption during the study period and a 4-week pre-study washout prior to study commencement. Study participants will be allowed to consume a daily multivitamin if they have been doing so at a stable dose for a minimum of three months prior to study commencement.

Exclusion Criteria:

  • Be younger than 18 years of age or older than 70 years of age;
  • Be an adult pre- or peri-menopausal female;
  • Not have taken Statin medication at a stable dose for a minimum of 4 weeks prior to study commencement;
  • Have fasting triglyceride levels outside of study limits[ie/ less than 1.5 mmol/L or greater than 5.7 mmol/L];
  • Have elevated fasting blood glucose levels [greater or equal to 7.0 mmol/L];
  • Have high blood pressure [greater than 140/100]
  • Have a Body Mass Index (BMI) equal to or greater than 35.0
  • Have a pre-existing cardiovascular disease or illness, including angina, myocardial infarction, stroke, intermittent claudication or transient ischemic attack;
  • Have a known allergy to fish and/or fish oil, olive oil, soy or Vitamin E;
  • Be taking natural health products but are unwilling to cease consumption during the study period and a 4-week pre-study washout prior to study commencement;
  • Consume more than two (2) fish meals on a weekly basis
  • Consume excessive amounts of alcohol on a weekly basis [more than 10 alcoholic drinks per week];
  • Anticipate or have planned surgery during the course of the study.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Crossover tilldelning
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: 1 (Dietary Supplement - Fish Oil)

On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed.

On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol.

On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of fish oil [620 mg of DHA and 150 mg of EPA], providing a total daily dosage of 4000 mg of fish oil [3080 mg of DHA+EPA].
Experimentell: 2 (Placebo)

On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed.

On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol.

On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of olive oil, providing a total daily dosage of 4000 mg of olive oil.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Triglyceride [TG]
Tidsram: 0 and 4 weeks
Fasted and postprandial samples will be drawn (hourly up to 6 hours).
0 and 4 weeks

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Glucose
Tidsram: 0 and 4 weeks
Fasted and postprandial samples will be drawn (every 30 minutes up to 2 hours).
0 and 4 weeks
Insulin
Tidsram: 0 and 4 weeks
Fasted and postprandial samples will be drawn (every 30 minutes up to 2 hours).
0 and 4 weeks
Total cholesterol [TC]
Tidsram: 0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
High-density lipoprotein [HDL]
Tidsram: 0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Low-density lipoprotein [LDL]
Tidsram: 0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Very low-density lipoprotein [VLDL]
Tidsram: 0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Lipoprotein A
Tidsram: 0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Intermediate-density lipoprotein [IDL]
Tidsram: 0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Remnant Lipoproteins
Tidsram: 0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
High-sensitivity C-Reactive Protein [hs-CRP]
Tidsram: 0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Homocysteine
Tidsram: 0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Essential Fatty Acid Profile
Tidsram: 0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Apolipoprotein B
Tidsram: 0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks
Apolipoprotein A-1
Tidsram: 0 and 4 weeks
A fasted blood sample will be taken.
0 and 4 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Alison Duncan, Ph.D., R.D., University of Guelph

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 september 2012

Primärt slutförande (Faktisk)

1 december 2013

Avslutad studie (Faktisk)

1 februari 2014

Studieregistreringsdatum

Först inskickad

10 september 2012

Först inskickad som uppfyllde QC-kriterierna

18 september 2012

Första postat (Uppskatta)

21 september 2012

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

7 februari 2014

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

6 februari 2014

Senast verifierad

1 februari 2014

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera